Diffractive Bremsstrahlung at High-β⋆\beta^\star LHC Case Study

Feasibility studies of the measurement of the exclusive diffractive bremsstrahlung cross-section in proton-proton scattering at the centre of mass energy of 13 TeV at the LHC are reported. Present studies were performed for the low luminosity LHC running with the betatron function value of 90~m using the ATLAS associated forward detectors ALFA and ZDC. A simplified approach to the event simulation and reconstruction is used. The background influence is also discussed.Comment: 20 pages, 10 figures. arXiv admin note: substantial text overlap with arXiv:1603.0644

Feasibility Studies of the Diffractive Bremsstrahlung Measurement at the LHC

Feasibility studies of an observation of the exclusive diffractive bremsstrahlung in proton-proton scattering at the LHC are reported. A simplified approach to the photon and the scattered proton energy reconstruction is used. The background influence is discussed.Comment: 15 pages, 6 figure

Tunable bandpass filter with two adjustable transmission poles and compensable coupling

published_or_final_versio

Human immunodeficiency virus rebound after suppression to < 400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression

This study evaluated 1433 human immunodeficiency virus (HIV)-infected patients starting highly active antiretroviral therapy (HAART), 409 (28%) of whom had prior nucleoside experience and achieved an HIV load of <400 copies/mL by 24 weeks of therapy. Three hundred seven patients experienced virus rebound during a total of 2773.3 person-years of follow-up. There was a higher rate of virus rebound among the patients with pre-HAART nucleoside experience (relative hazard [RH], 2.86; 95% confidence interval, 2.22-3.84; P < .0001) and a decreasing rate of virus rebound with increasing duration of virus suppression (i.e., time since achieving a virus load of <400 HIV RNA copies/mL) among both the nucleoside-experienced and naive patients (P < .0001), but the difference between the groups persisted into the third year of follow-up (P = .0007). Even patients who had experienced <2 months of nucleoside therapy before beginning HAART had an increased risk of virus rebound (RH, 1.95; P = .009). It appears that only a small period of pre-HAART nucleoside therapy is sufficient to confer a disadvantage, in terms of risk of virus rebound, that persists for several years

Mutations in the C-terminal region of the HIV-1 reverse transcriptase and their correlation with drug resistance associated mutations and antiviral treatment

<p>Abstract</p> <p>Objective</p> <p>Replication of HIV-1 after cell entry is essentially dependent on the reverse transcriptase (RT). Antiretroviral drugs impairing the function of the RT currently aim at the polymerase subunit. One reason for failure of antiretroviral treatment is the evolvement of resistance-associated mutations in the viral genome. For RT inhibitors, almost all identified mutations are located within the polymerase; therefore, general genotyping confines to investigate this subunit. Recently several studies have shown that substitutions within the RNase H and the connection domain increase antiviral drug-resistance in vitro, and some of them are present in patient isolates.</p> <p>Aim</p> <p>The aim of the present study was to investigate the prevalence of these substitutions and their association with mutations in the polymerase domain arising during antiretroviral treatment.</p> <p>Materials and methods</p> <p>We performed genotypic analyzes on seventy-four virus isolates derived from treated and untreated patients, followed at the HIV Centre of the Johann Wolfgang Goethe University Hospital (Frankfurt/Main, Germany). We subsequently analysed the different substitutions in the c-terminal region to evaluate whether there were associations with each other, n-terminal substitutions or with antiretroviral treatment.</p> <p>Results</p> <p>We identified several primer grip substitutions, but almost all of them were located in the connection domain. This is consistent with other in-vivo studies, in which especially the primer grip residues located in the RNase H were unvaried. Furthermore, we identified other substitutions in the connection domain and in the RNase H. Especially E399D seemed to be associated with an antiretroviral treatment and N-terminal resistance-delivering mutations.</p> <p>Conclusion</p> <p>Some of the identified substitutions were associated with antiviral treatment and drug resistance-associated mutations. Due to the low prevalence of C-terminal mutations and as only a few of them could be associated with antiviral treatment and N-terminal resistance-delivering mutations, we would not recommend routinely testing of the C-terminal RT region.</p

Novel Electromagnetic Sensors Embedded in Reinforced Concrete Beams for Crack Detection

This paper investigates the possibility of applying novel microwave sensors for crack detection in reinforced concrete structures. Initially, a microstrip patch antenna with a Split Ring Resonator (SRR) structure was designed, simulated and fabricated. To evaluate the sensor’s performance, a series of structural tests were carried out and the sensor responses were monitored. Four reinforced concrete (RC) beam specimens, designed according to the European Standards, were tested under 3-point bending. The load was applied incrementally to the beams and the static responses were monitored via the use of a load cell, displacement transducers and crack width gauges (Demec studs). In parallel, signal readings from the microwave sensors, which were employed prior to casting of the concrete, located at the neutral axis at the mid-span of the beam, were recorded at various load increments. The microwave measurements were analysed and compared with those from crack width gauges. A strong linear relationship between the crack propagation and the electromagnetic signal across the full captured spectrum was found, demonstrating the technique’s capability and its potential for further research offering a reliable, low cost option for structural health monitoring (SHM)

Damage detection and location in woven fabric CFRP laminate panels

The need for multifunctional carbon fibre composite laminates has emerged to improve the reliability and safety of carbon fibre composite components and decrease costs. The development of an electrical selfsensing system for woven fabric carbon fibre composite laminate panels which can detect and locate damage due to impact events is presented. The electrical sensing system uses a four probe electrical resistance method. Two different sensing mats are investigated, the main difference between them are the surface area of the electrodes and the distance between the electrodes. To investigate the damage sensitivity of the sensing system for woven fabric carbon fibre composite laminate panels, panels are produced with various thicknesses from 0.84 to 3.5 mm and are impacted at energies from 1 to 10 J to generate barely visible impact damage. Damage is detected using global electrical resistance changes, the changes in electrical resistance vary depending on carbon fibre volume fraction, spacing distance between the sensing electrodes in the sensing mats, the surface area of the electrodes, damage size, and damage type; it is found that the thicker the panel, the less sensitive the electrical resistance system is. The effect of the surface area of the sensing electrodes is high on the electrical resistance baseline, where the baseline increases by up to 55% when the surface area of the sensing electrodes increases from 100 mm2 to 400 mm2; while spacing distance between electrodes has a greater effect on damage sensitivity of the electrical resistance sensing system than the surface area of the sensing electrodes

Time to Virological Failure of 3 Classes of Antiretrovirals after Initiation of Highly Active Antiretroviral Therapy: Results from the EuroSIDA Study Group

Objective. The purpose of the present study was to determine the prevalence and incidence of virological triple drug-class failure (TCF) and to summarize the clinical outcome for patients who started receiving highly active antiretroviral therapy (HAART). Methods. The present study is an observational longitudinal study of 3496 treatment-experienced (TE) and treatment-naive (TN) patients monitored from the time they started receiving HAART (baseline) until TCF occurred (as determined on the basis of viral loads), until AIDS was newly diagnosed, or until death. Results. Four hundred forty-five patients (12.7%) had TCF; 370 (16.6%) of 2230 patients were TE, and 75 (5.9%) of 1266 patients were TN. At 6 years after starting HAART, 21.4% of TE and 11.2% of TN patients had TCF (P < .0001). The prevalence of TCF at or after 2002 was 15.5% in TE patients and 4.8% in TN patients. TN patients had a 32% annual increase in the incidence of TCF (95% confidence interval [CI], 14%-54%; P < .0001); at 5 years after starting HAART, the rate was comparable for TE and TN patients (3.3 and 3.4 cases/100 person-years of follow-up [PYFU], respectively). The incidence of new cases of AIDS or death was 2.7 cases/100 PYFU in patients who did not experience TCF and 5.0 cases/100 PYFU in patients who did experience TCF, an estimated 36% increase with each category of TCF (95% CI, 19%-56%; P < .0001). Conclusion. The prevalence of TCF was low after patients started receiving HAART, particularly among TN patients. Despite the influx of patients who had started receiving HAART more recently, the prevalence of TCF increased over calendar time. Patients with TCF had a higher incidence of newly diagnosed AIDS or death. Treatment of patients with TCF deserves further investigatio